{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:55:40Z","timestamp":1787972140840,"version":"build-2784847793"},"update-to":[{"DOI":"10.1002\/14651858.cd008876.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,12,17]],"date-time":"2013-12-17T00:00:00Z","timestamp":1387238400000}}],"reference-count":135,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008876.pub3","type":"journal-article","created":{"date-parts":[[2013,12,17]],"date-time":"2013-12-17T02:30:47Z","timestamp":1387247447000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Pharmacological treatment for memory disorder in multiple sclerosis"],"prefix":"10.1002","volume":"2013","author":[{"given":"Dian","family":"He","sequence":"first","affiliation":[{"name":"Affiliated Hospital of Guiyang Medical College; Department of Neurology; No. 28, Gui Yi Street Guiyang Guizhou Province China 550004"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Jinan No. 6 People's Hospital; Clinical Laboratory; No. 38, Hui Quan Road Jinan Shandong Province China 250200"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Dong","sequence":"additional","affiliation":[{"name":"Jinan No. 6 People's Hospital; Department of Neurology; No. 38, Hui Quan Road Jinan Shandong Province China 250200"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Jinan No. 6 People's Hospital; Department of Neurology; No. 38, Hui Quan Road Jinan Shandong Province China 250200"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangdong","family":"Gao","sequence":"additional","affiliation":[{"name":"Jinan No. 6 People's Hospital; Department of Neurology; No. 38, Hui Quan Road Jinan Shandong Province China 250200"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Zhou","sequence":"additional","affiliation":[{"name":"West China Hospital, Sichuan University; Department of Neurology; No. 37, Guo Xue Xiang Chengdu Sichuan China 610041"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,12,17]]},"reference":[{"issue":"9","key":"10.1002\/14651858.CD008876.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1212\/01.WNL.0000142989.09633.5A","article-title":"Donepezil improved memory in multiple sclerosis in a randomized clinical trial","volume":"63","author":"Krupp","year":"2004","journal-title":"Neurology"},{"issue":"17","key":"10.1002\/14651858.CD008876.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1212\/WNL.0b013e318218107a","article-title":"Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis","volume":"76","author":"Krupp","year":"2011","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD008876.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1177\/1352458506071213","article-title":"Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial","volume":"13","author":"Lovera","year":"2007","journal-title":"Multiple Sclerosis"},{"issue":"6","key":"10.1002\/14651858.CD008876.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1177\/1352458510367662","article-title":"Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial","volume":"16","author":"Lovera","year":"2010","journal-title":"Multiple Sclerosis"},{"issue":"12","key":"10.1002\/14651858.CD008876.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1212\/WNL.0b013e31826aac60","article-title":"Ginkgo biloba does not improve cognitive function in MS: a randomized placebo-controlled trial","volume":"79","author":"Lovera","year":"2012","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD008876.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1177\/1352458512463481","article-title":"Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients","volume":"19","author":"M\u00e4urer","year":"2013","journal-title":"Multiple Sclerosis"},{"issue":"4","key":"10.1002\/14651858.CD008876.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1017\/S0317167100009148","article-title":"Effects of rivastigmine on memory and cognition in multiple sclerosis","volume":"35","author":"Shaygannejad","year":"2008","journal-title":"Canadian Journal of Neurological Sciences"},{"issue":"1","key":"10.1002\/14651858.CD008876.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/WNF.0b013e3181633497","article-title":"Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study","volume":"32","author":"Aragona","year":"2009","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/13651509909024756","article-title":"Neuropsychiatric assessment as a secondary outcome measure in a multiple sclerosis intravenous immunoglobulin (IVIg) trial","volume":"3","author":"Barak","year":"1999","journal-title":"International Journal of Psychiatry in Clinical Practice"},{"issue":"1","key":"10.1002\/14651858.CD008876.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000047940","article-title":"Effect of interferon-beta-1b on cognitive functions in multiple sclerosis","volume":"47","author":"Barak","year":"2002","journal-title":"European Neurology"},{"issue":"6","key":"10.1002\/14651858.CD008876.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/s00415-008-0760-7","article-title":"Effects of l-amphetamine sulfate on cognitive function in multiple sclerosis patients","volume":"255","author":"Benedict","year":"2008","journal-title":"Journal of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD008876.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1212\/WNL.47.6.1457","article-title":"Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial","volume":"47","author":"Bever","year":"1996","journal-title":"Neurology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD008876.pub3-BIB0013|cit13","first-page":"S150","article-title":"Donepezile and cognitive impairment in multiple sclerosis: a double-blind pilot study","volume":"10","author":"Bosca","year":"2004","journal-title":"Multiple Sclerosis"},{"issue":"3","key":"10.1002\/14651858.CD008876.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/WNN.0b013e31826df7fd","article-title":"Impact of armodafinil on cognition in multiple sclerosis: a randomized, double-blind crossover pilot study","volume":"25","author":"Bruce","year":"2012","journal-title":"Cognitive and Behavioral Neurology"},{"issue":"3","key":"10.1002\/14651858.CD008876.pub3-BIB0015|cit15","first-page":"214","article-title":"Interferon-alpha2b recombinant improved the cognitive dysfunction in patients with relapsing remitting multiple sclerosis","volume":"37","author":"Cabrera-Gomez","year":"2003","journal-title":"Revista de Neurologia"},{"issue":"1-2","key":"10.1002\/14651858.CD008876.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jns.2005.08.021","article-title":"Effects of donepezil on memory and cognition in multiple sclerosis","volume":"245","author":"Christodoulou","year":"2006","journal-title":"Journal of Neurological Sciences"},{"issue":"6","key":"10.1002\/14651858.CD008876.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/archneur.1989.00520420096030","article-title":"Amantadine treatment of fatigue associated with multiple sclerosis","volume":"46","author":"Cohen","year":"1989","journal-title":"Archives of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD008876.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1212\/WNL.59.5.679","article-title":"Benefit of interferon beta-1a on MSFC progression in secondary progressive MS","volume":"59","author":"Cohen","year":"2002","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD008876.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD008876.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1056\/NEJMoa1104318","article-title":"Placebo-controlled trial of oral laquinimod for multiple sclerosis","volume":"366","author":"Comi","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD008876.pub3-BIB0021|cit21","first-page":"S150","article-title":"Effects of donepezil in multiple sclerosis: a single-centre trial","volume":"10","author":"Decoo","year":"2004","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0022|cit22","first-page":"289","article-title":"Low dose (7.5 mg) oral methotrexate improves neurophysiological function in patients with chronic progressive multiple sclerosis","volume":"36","author":"Fischer","year":"1994","journal-title":"Annals of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD008876.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/1531-8249(200012)48:6<885::AID-ANA9>3.0.CO;2-1","article-title":"Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group","volume":"48","author":"Fischer","year":"2000","journal-title":"Annals of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD008876.pub3-BIB0024|cit24","first-page":"457","article-title":"Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study","volume":"9","author":"Flechter","year":"2007","journal-title":"The Israel Medical Association Journal"},{"issue":"2","key":"10.1002\/14651858.CD008876.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/archneur.1996.00550020101021","article-title":"The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis","volume":"53","author":"Geisler","year":"1996","journal-title":"Archives of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD008876.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/00004714-200006000-00010","article-title":"A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments","volume":"20","author":"Greene","year":"2000","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1-2","key":"10.1002\/14651858.CD008876.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jns.2008.08.025","article-title":"Single dose of methylphenidate improves cognitive performance in multiple sclerosis patients with impaired attention process","volume":"276","author":"Harel","year":"2009","journal-title":"Journal of Neurological Sciences"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD008876.pub3-BIB0028|cit28","first-page":"307","article-title":"The effects of natalizumab on a test of cognitive function in patients with relapsing multiple sclerosis (MS) [abstract]","volume":"13","author":"Havrdova","year":"2006","journal-title":"European Journal of Neurology"},{"issue":"13","key":"10.1002\/14651858.CD008876.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1212\/WNL.0b013e318212ab0c","article-title":"Effects of cannabis on cognitive function in patients with multiple sclerosis","volume":"76","author":"Honarmand","year":"2011","journal-title":"Neurology"},{"issue":"11","key":"10.1002\/14651858.CD008876.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1177\/1352458511412061","article-title":"The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue","volume":"17","author":"Huolman","year":"2011","journal-title":"Multiple Sclerosis"},{"issue":"4","key":"10.1002\/14651858.CD008876.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"e35843","DOI":"10.1371\/journal.pone.0035843","article-title":"Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study","volume":"7","author":"Iaffaldano","year":"2012","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0032|cit32","first-page":"S313","article-title":"Laquinimod's impact on patient-reported fatigue and functional status: results from Allegro, a placebo-controlled phase III trial for relapsing-remitting multiple sclerosis","volume":"17","author":"Jeffery","year":"2011","journal-title":"Multiple Sclerosis"},{"issue":"5","key":"10.1002\/14651858.CD008876.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0034|cit34","first-page":"S46","article-title":"Cognitive dysfunction in relapsing-remitting multiple sclerosis: relation to quality of life and longitudinal changes under treatment with natalizumab","volume":"18","author":"Krause","year":"2012","journal-title":"Multiple Sclerosis"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD008876.pub3-BIB0035|cit35","first-page":"A137","article-title":"Donepezil for the treatment of memory impairments in multiple sclerosis","volume":"52","author":"Krupp","year":"1999","journal-title":"Neurology"},{"issue":"13","key":"10.1002\/14651858.CD008876.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1177\/1352458513485981","article-title":"The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study","volume":"19","author":"Lacy","year":"2013","journal-title":"Multiple Sclerosis"},{"issue":"3","key":"10.1002\/14651858.CD008876.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000334722","article-title":"Natalizumab may improve cognition and mood in multiple sclerosis","volume":"67","author":"Lang","year":"2012","journal-title":"European Neurology"},{"issue":"4","key":"10.1002\/14651858.CD008876.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00415-009-0152-7","article-title":"Modafinil effects in multiple sclerosis patients with fatigue","volume":"256","author":"Lange","year":"2009","journal-title":"Journal of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD008876.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10072-010-0412-4","article-title":"The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study","volume":"32","author":"Mattioli","year":"2011","journal-title":"Neurological Sciences"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD008876.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10072-010-0351-0","article-title":"Natalizumab efficacy on cognitive impairment in MS","volume":"31","author":"Mattioli","year":"2011","journal-title":"Neurological Sciences"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3109\/00207454.2010.511732","article-title":"Fatigue and cognition in patients with relapsing multiple sclerosis treated with interferon beta","volume":"120","author":"Melanson","year":"2010","journal-title":"International Journal of Neuroscience"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0042|cit42","first-page":"S182","article-title":"Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase III trial (TEMSO)","volume":"17","author":"Miller","year":"2011","journal-title":"Multiple Sclerosis"},{"issue":"8","key":"10.1002\/14651858.CD008876.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1177\/1352458511402410","article-title":"\u00a0HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis","volume":"17","author":"M\u00f6ller","year":"2011","journal-title":"Multiple Sclerosis"},{"issue":"10","key":"10.1002\/14651858.CD008876.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1177\/1352458509106937","article-title":"A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis","volume":"15","author":"Montalban","year":"2009","journal-title":"Multiple Sclerosis"},{"issue":"7","key":"10.1002\/14651858.CD008876.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s00415-009-5074-x","article-title":"The effects of L-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trial","volume":"256","author":"Morrow","year":"2009","journal-title":"Journal of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD008876.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00415-012-6663-7","article-title":"Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study","volume":"260","author":"Morrow","year":"2013","journal-title":"Journal of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD008876.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1600-0404.1998.tb05967.x","article-title":"Pulsed methylprednisolone induces a reversible impairment of memory in patients with relapsing-remitting multiple sclerosis","volume":"97","author":"Oliveri","year":"1998","journal-title":"Acta Neurologica Scandinavica"},{"issue":"10","key":"10.1002\/14651858.CD008876.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1212\/01.WNL.0000146958.77317.3E","article-title":"Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study","volume":"63","author":"Panitch","year":"2004","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD008876.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/1756285608101379","article-title":"Subcutaneous interferon beta-1a has a positive effect on cognitive performance in mildly disabled patients with relapsing-remitting multiple sclerosis: 2-year results from the COGIMUS study","volume":"2","author":"Patti","year":"2009","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"1","key":"10.1002\/14651858.CD008876.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/1352458509350309","article-title":"Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis","volume":"16","author":"Patti","year":"2010","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0051|cit51","first-page":"326","article-title":"The effects of interferon-beta on cognitive function in multiple sclerosis","volume":"36","author":"Pliskin","year":"1994","journal-title":"Annals of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD008876.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1212\/WNL.47.6.1463","article-title":"Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b","volume":"47","author":"Pliskin","year":"1996","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD008876.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1468-1331.2012.03882.x","article-title":"Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis: a prospective, non-randomized pilot study","volume":"20","author":"Portaccio","year":"2013","journal-title":"European Journal of Neurology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD008876.pub3-BIB0054|cit54","first-page":"A99","article-title":"Effects of donepezil on cognitive function in patients with multiple sclerosis","volume":"56","author":"Rorie","year":"2001","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD008876.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1177\/135245850100700602","article-title":"Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine","volume":"7","author":"Rossini","year":"2001","journal-title":"Multiple Sclerosis"},{"issue":"9","key":"10.1002\/14651858.CD008876.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008876.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1055\/s-2000-7966","article-title":"Amantadine influences cognitive processing in patients with multiple sclerosis","volume":"33","author":"Sailer","year":"2000","journal-title":"Pharmacopsychiatry"},{"issue":"7","key":"10.1002\/14651858.CD008876.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.clineuro.2011.02.018","article-title":"Stability of cognitive functions under mitoxantrone therapy in patients with progressive multiple sclerosis: a pilot analysis","volume":"113","author":"Schr\u00f6der","year":"2011","journal-title":"Clinical Neurology and Neurosurgery"},{"issue":"1-2","key":"10.1002\/14651858.CD008876.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jns.2007.01.070","article-title":"Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial","volume":"255","author":"Schwid","year":"2007","journal-title":"Journal of Neurological Sciences"},{"issue":"3 Pt 1","key":"10.1002\/14651858.CD008876.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.2466\/pms.1998.86.3.1099","article-title":"Interferon beta 1-b in verbal memory functioning of patients with relapsing-remitting multiple sclerosis","volume":"86","author":"Selby","year":"1998","journal-title":"Perceptual and Motor Skills"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0061|cit61","doi-asserted-by":"crossref","unstructured":"Selmaj K Havrdova E Gold R Greenberg S Umans K Elkins J Daclizumab Hyp monotherapy improved health-related quality of life parameters in relapsing-remitting multiple sclerosis: findings of the SELECT trial Neurology 2012","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.P07.098"},{"issue":"9","key":"10.1002\/14651858.CD008876.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1212\/WNL.44.9.1701","article-title":"The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study","volume":"44","author":"Smits","year":"1994","journal-title":"Neurology"},{"issue":"9","key":"10.1002\/14651858.CD008876.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1177\/1352458511404585","article-title":"L-amphetamine improves memory in MS patients with objective memory impairment","volume":"17","author":"Sumowski","year":"2011","journal-title":"Multiple Sclerosis"},{"issue":"11","key":"10.1002\/14651858.CD008876.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1212\/01.WNL.0000163804.94163.91","article-title":"Reversible impaired memory induced by pulsed methylprednisolone in patients with MS","volume":"64","author":"Uttner","year":"2005","journal-title":"Neurology"},{"issue":"19","key":"10.1002\/14651858.CD008876.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1212\/01.wnl.0000342388.73185.80","article-title":"Memantine induces reversible neurologic impairment in patients with MS","volume":"72","author":"Villoslada","year":"2009","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD008876.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1191\/1352458504ms1082oa","article-title":"Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients","volume":"10","author":"Wade","year":"2004","journal-title":"Multiple Sclerosis"},{"issue":"3","key":"10.1002\/14651858.CD008876.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/archneur.56.3.319","article-title":"Neuropsychologic status in multiple sclerosis after treatment with glatiramer","volume":"56","author":"Weinstein","year":"1999","journal-title":"Archives of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD008876.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s00415-011-6275-7","article-title":"Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS","volume":"259","author":"Weinstock-Guttman","year":"2012","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0069|cit69","doi-asserted-by":"crossref","unstructured":"Weinstock-Guttman B Cree B de Seze J Fox R Gold R Hartung H Effects of a 24-week natalizumab treatment interruption on quality of life, fatigue, and cognition: results from the RESTORE Study Neurology 2012 P06.171","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.P06.171"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0070|cit70","first-page":"68","article-title":"Combination therapy (Provigil + Avonex) in the treatment of cognitive problems in MS [abstract]","volume":"6","author":"Wilken","year":"2004","journal-title":"International Journal of MS Care"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7224\/1537-2073-10.1.1","article-title":"Treatment of multiple sclerosis-related cognitive problems with adjunctive modafinil: rationale and preliminary supportive data","volume":"10","author":"Wilken","year":"2008","journal-title":"International Journal of MS Care"},{"issue":"3","key":"10.1002\/14651858.CD008876.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1191\/1352458505ms1172sr","article-title":"One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis","volume":"11","author":"Z\u00e9phir","year":"2005","journal-title":"Multiple Sclerosis"},{"issue":"1","key":"10.1002\/14651858.CD008876.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.neurol.2007.08.003","article-title":"Cognitive impact of mitoxantrone and methylprednisolone in multiple sclerosis: an open label study","volume":"164","author":"Z\u00e9phir","year":"2008","journal-title":"Revue Neurologique (Paris)"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0074|cit74","unstructured":"NCT01074619 Study on cognitive disorders of multiple sclerosis clinicaltrials.gov\/ct2\/show\/NCT01074619"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0075|cit75","unstructured":"NCT01466114 Estriol treatment in multiple sclerosis (MS): effect on cognition clinicaltrials.gov\/ct2\/show\/NCT01466114"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s00018-003-3080-1","article-title":"Neuroprotective effects of Ginkgo biloba extract","volume":"60","author":"Ahlemeyer","year":"2003","journal-title":"Cellular Molecular Life Sciences"},{"issue":"1","key":"10.1002\/14651858.CD008876.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1212\/01.WNL.0000129544.79539.D5","article-title":"Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment","volume":"63","author":"Amato","year":"2004","journal-title":"Neurology"},{"issue":"1-2","key":"10.1002\/14651858.CD008876.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jns.2005.07.017","article-title":"Are there protective treatments for cognitive decline in MS?","volume":"245","author":"Amato","year":"2006","journal-title":"Journal of the Neurological Sciences"},{"issue":"3","key":"10.1002\/14651858.CD008876.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1191\/1352458503ms904oa","article-title":"Fatigue associated with multiple sclerosis: diagnosis, impact and management","volume":"9","author":"Bakshi","year":"2003","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0080|cit80","volume-title":"Brief Visuospatial Memory Test-Revised: Professional Manual","author":"Benedict","year":"1997"},{"issue":"7","key":"10.1002\/14651858.CD008876.pub3-BIB0081|cit81","first-page":"1824","article-title":"Regional lobar atrophy predicts memory impairment in multiple sclerosis","volume":"26","author":"Benedict","year":"2005","journal-title":"American Journal of Neuroradiology"},{"issue":"4","key":"10.1002\/14651858.CD008876.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1017\/S1355617706060723","article-title":"Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS)","volume":"12","author":"Benedict","year":"2006","journal-title":"Journal of the International Neuropsychological Society"},{"issue":"2","key":"10.1002\/14651858.CD008876.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/jnnp.2008.148403","article-title":"Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy","volume":"80","author":"Benedict","year":"2009","journal-title":"Journal of Neurology Neurosurgery and Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD008876.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/135245850100700409","article-title":"The brief repeatable battery of neuropsychological tests: normative values allow application in multiple sclerosis clinical practice","volume":"7","author":"Boringa","year":"2001","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1212\/WNL.24.11.1019","article-title":"Evaluating storage, retention and retrieval in disordered memory and learning","volume":"24","author":"Buschke","year":"1974","journal-title":"Neurology"},{"issue":"9","key":"10.1002\/14651858.CD008876.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1001\/archneurol.2009.174","article-title":"Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis","volume":"66","author":"Calabrese","year":"2009","journal-title":"Archives of Neurology"},{"issue":"Pt 10","key":"10.1002\/14651858.CD008876.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1093\/brain\/aws246","article-title":"Cortical lesion load associates with progression of disability in multiple sclerosis","volume":"135","author":"Calabrese","year":"2012","journal-title":"Brain"},{"issue":"1","key":"10.1002\/14651858.CD008876.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1212\/WNL.47.1.129","article-title":"Validation of the functional assessment of multiple sclerosis quality of life instrument","volume":"47","author":"Cella","year":"1996","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD008876.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S1474-4422(08)70259-X","article-title":"Cognitive impairment in multiple sclerosis","volume":"7","author":"Chiaravalloti","year":"2008","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0090|cit90","volume-title":"California Verbal Learning Test","author":"Delis","year":"2000"},{"issue":"Pt 1","key":"10.1002\/14651858.CD008876.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/brain\/awn275","article-title":"Disconnection as a mechanism for cognitive dysfunction in multiple sclerosis","volume":"132","author":"DineenRA","year":"2009","journal-title":"Brain"},{"issue":"1","key":"10.1002\/14651858.CD008876.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/1352458506071196","article-title":"Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis","volume":"13","author":"Feuillet","year":"2007","journal-title":"Multiple Sclerosis"},{"issue":"4","key":"10.1002\/14651858.CD008876.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/135245859900500410","article-title":"Recent developments in the assessment of quality of life in multiple sclerosis (MS)","volume":"5","author":"Fischer","year":"1999","journal-title":"Multiple Sclerosis"},{"issue":"4","key":"10.1002\/14651858.CD008876.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/jnnp.64.4.529","article-title":"Neuropsychological deficits in multiple sclerosis after acute relapse","volume":"64","author":"Foong","year":"1998","journal-title":"Journal of Neurology Neurosurgery and Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD008876.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/S1474-4422(12)70230-2","article-title":"Measurement and clinical effect of grey matter pathology in multiple sclerosis","volume":"11","author":"Geurts","year":"2012","journal-title":"Lancet Neurology"},{"issue":"1","key":"10.1002\/14651858.CD008876.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/jnnp.2010.237834","article-title":"Cognitive deterioration in patients with early multiple sclerosis: a 5-year study","volume":"83","author":"Glanz","year":"2012","journal-title":"Journal of Neurology Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0097|cit97","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejphar.2004.04.051","article-title":"Ginkgolides, diterpene trilactones of Ginkgo biloba, as antagonists at recombinant alpha1beta2gamma2L GABAA receptors","volume":"494","author":"Huang","year":"2004","journal-title":"European Journal of Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD008876.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1212\/01.WNL.0000129828.03714.90","article-title":"Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS","volume":"63","author":"Huijbregts","year":"2004","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD008876.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1037\/a0019222","article-title":"Relationship between depression, fatigue, subjective cognitive impairment, and objective neuropsychological functioning in patients with multiple sclerosis","volume":"24","author":"Kinsinger","year":"2010","journal-title":"Neuropsychology"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1523\/JNEUROSCI.15-02-01308.1995","article-title":"Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine","volume":"15","author":"Kuczenski","year":"1995","journal-title":"The Journal of Neuroscience"},{"issue":"2","key":"10.1002\/14651858.CD008876.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1136\/jnnp.69.2.192","article-title":"Electroencephalographic coherence analysis in multiple sclerosis: correlation with clinical, neuropsychological, and MRI findings","volume":"69","author":"Leocani","year":"2000","journal-title":"Journal of Neurology Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0103|cit103","volume-title":"Neuropsychological Assessment","author":"Lezak","year":"2004"},{"issue":"1","key":"10.1002\/14651858.CD008876.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Annals of Neurology"},{"issue":"13","key":"10.1002\/14651858.CD008876.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1212\/WNL.0b013e31824d5859","article-title":"Diffusion tensor MRI tractography and cognitive impairment in multiple sclerosis","volume":"78","author":"Mesaros","year":"2012","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD008876.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.neuroimage.2005.10.032","article-title":"Evidence for a direct association between cortical atrophy and cognitive impairment in relapsing-remitting MS","volume":"30","author":"Morgen","year":"2006","journal-title":"Neuroimage"},{"issue":"9","key":"10.1002\/14651858.CD008876.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s00415-011-5975-3","article-title":"Effects of acute relapses on neuropsychological status in multiple sclerosis patients","volume":"258","author":"Morrow","year":"2011","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1054\/mehy.2000.1099","article-title":"Can the cognitive enhancing effects of Ginkgo biloba be explained by its pharmacology?","volume":"55","author":"Nathan","year":"2000","journal-title":"Medical Hypotheses"},{"issue":"2","key":"10.1002\/14651858.CD008876.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1006\/nimg.1996.0032","article-title":"Functional basis of memory impairment in multiple sclerosis: a [18F] FDG PET study","volume":"4","author":"Paulesu","year":"1996","journal-title":"Neuroimage"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/71555","article-title":"Glutamate excitotoxicity in a model of multiple sclerosis","volume":"6(1)","author":"Pitt","year":"2000","journal-title":"Nature Medicine"},{"issue":"6","key":"10.1002\/14651858.CD008876.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \"McDonald Criteria\"","volume":"58","author":"Polman","year":"2005","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD008876.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Annals of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD008876.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Annals of Neurology"},{"issue":"1-2","key":"10.1002\/14651858.CD008876.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jns.2007.10.002","article-title":"Cognitive impairment in different MS subtypes and clinically isolated syndromes","volume":"267","author":"Potagas","year":"2008","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0115|cit115","volume-title":"A Manual for the Brief, Repeatable Battery of Neuropsychological Tests in Multiple Sclerosis","author":"Rao","year":"1990"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0116|cit116","volume-title":"Cognitive Function Study Group, NMSS. A Manual for the Brief Repeatable Battery of Neuropsychological Tests in Multiple Sclerosis","author":"Rao","year":"1990"},{"issue":"5","key":"10.1002\/14651858.CD008876.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1212\/WNL.41.5.685","article-title":"Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction","volume":"41","author":"Rao","year":"1991","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1212\/WNL.41.5.692","article-title":"Cognitive dysfunction in multiple sclerosis: II. Impact on employment and social functioning","volume":"41","author":"Rao","year":"1991","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0119|cit119","volume-title":"Neuropsychological Screening Battery for Multiple Sclerosis","author":"Rao","year":"1991"},{"issue":"3","key":"10.1002\/14651858.CD008876.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1037\/0894-4105.7.3.364","article-title":"Memory dysfunction in multiple sclerosis: its relation to working memory, semantic encoding, and implicit learning","volume":"7","author":"Rao","year":"1993","journal-title":"Neuropsychology"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0121|cit121","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2013"},{"issue":"11","key":"10.1002\/14651858.CD008876.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"e44826","DOI":"10.1371\/journal.pone.0044826","article-title":"Relevance of brain lesion location to cognition in relapsing multiple sclerosis","volume":"7","author":"Rossi","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1002\/14651858.CD008876.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1136\/jnnp.50.5.538","article-title":"Acetylcholinesterase and butyrylcholinesterase activity in the cerebrospinal fluid of patients with neurodegenerative diseases involving cholinergic systems","volume":"50","author":"Ruberg","year":"1987","journal-title":"Journal of Neurology Neurosurgery and Psychiatry"},{"issue":"16","key":"10.1002\/14651858.CD008876.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1212\/WNL.0b013e31828cf82f","article-title":"Cognitive impairment differs between primary progressive and relapsing-remitting MS","volume":"80","author":"Ruet","year":"2013","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD008876.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1212\/01.wnl.0000201238.93586.d9","article-title":"Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis","volume":"66","author":"Sanfilipo","year":"2006","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0126|cit126","unstructured":"Sch\u00fcnemann H Bro\u017cek J Oxman A GRADE Handbook for Grading Quality of Evidence and Strength of Recommendation. Version 3.2 [updated March 2009]. The GRADE Working Group http:\/\/www.cc-ims-net\/gradepro 2009"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0127|cit127","volume-title":"Symbol Digit Modalities Test (SDMT)","author":"Smith","year":"1982"},{"issue":"3","key":"10.1002\/14651858.CD008876.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1017\/S1355617702813200","article-title":"Memory in multiple sclerosis: contextual encoding deficits","volume":"8","author":"Thornton","year":"2002","journal-title":"Journal of the International Neuropsychological Society"},{"issue":"12","key":"10.1002\/14651858.CD008876.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/01.jnen.0000190067.20935.42","article-title":"Grey matter pathology in multiple sclerosis","volume":"64","author":"Vercellino","year":"2005","journal-title":"Journal of Neuropathology and Experimental Neurology"},{"issue":"3","key":"10.1002\/14651858.CD008876.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF02260859","article-title":"A health-related quality of life measure for multiple sclerosis","volume":"4","author":"Vickrey","year":"1995","journal-title":"Quality of Life Research"},{"issue":"6","key":"10.1002\/14651858.CD008876.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Medical Care"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0132|cit132","volume-title":"Wechsler Memory Scale-Revised","author":"Wechsler","year":"1987"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0133|cit133","volume-title":"Wechsler Memory Scale - Third Edition (WMS-III)","author":"Wechsler","year":"1997"},{"key":"10.1002\/14651858.CD008876.pub3-BIB0134|cit134","volume-title":"Wechsler Adult Intelligence Scale","author":"Wechsler","year":"1997"},{"issue":"10","key":"10.1002\/14651858.CD008876.pub3-BIB0135|cit135","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008876","article-title":"Pharmacologic treatment for memory disorder in multiple sclerosis","author":"He","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD008876.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:05:13Z","timestamp":1742774713000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008876.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,12,17]]},"references-count":135,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2013,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008876.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,17]]}}}